Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B.

Tatton W, Chalmers-Redman R, Tatton N.

J Neural Transm (Vienna). 2003 May;110(5):509-15. Review.

PMID:
12721812
2.

Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes.

Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M.

Neurotoxicol Teratol. 2002 Sep-Oct;24(5):675-82. Review.

PMID:
12200198
3.

(-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.

Tatton WG, Wadia JS, Ju WY, Chalmers-Redman RM, Tatton NA.

J Neural Transm Suppl. 1996;48:45-59. Review.

PMID:
8988461
4.

[Molecular mechanisms of the neuroprotective effect of (-)-deprenyl].

Pálfi M, Szökó E, Kálmán M.

Orv Hetil. 2006 Jul 9;147(27):1251-7. Review. Hungarian.

PMID:
16927880
5.

(-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.

Magyar K, Szende B.

Neurotoxicology. 2004 Jan;25(1-2):233-42. Review.

PMID:
14697898
6.

Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.

Jenner P.

Neurology. 2004 Oct 12;63(7 Suppl 2):S13-22. Review. No abstract available.

PMID:
15477581
7.

Apoptotic mechanisms in neurodegeneration: possible relevance to glaucoma.

Tatton WG.

Eur J Ophthalmol. 1999 Jan-Mar;9 Suppl 1:S22-9. Review.

PMID:
10230602
9.

Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription.

Tatton WG, Chalmers-Redman RM, Ju WY, Wadia J, Tatton NA.

J Neural Transm Suppl. 1997;49:245-68. Review.

PMID:
9266433
10.
11.

Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases.

Berry MD, Boulton AA.

Neurotoxicol Teratol. 2002 Sep-Oct;24(5):667-73. Review.

PMID:
12200197
12.

Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.

Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T.

J Neurosci Res. 2005 Jan 1-15;79(1-2):172-9. Review.

PMID:
15573406
13.
14.

Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.

Naoi M, Maruyama W, Inaba-Hasegawa K.

Expert Rev Neurother. 2013 Jun;13(6):671-84. doi: 10.1586/ern.13.60. Review.

PMID:
23739004
15.
16.

[History of deprenyl--the first selective inhibitor of monoamine oxidase type B].

Knoll J.

Vopr Med Khim. 1997 Nov-Dec;43(6):482-93. Review. Russian.

PMID:
9503565
17.

The pharmacology of selegiline.

Magyar K.

Int Rev Neurobiol. 2011;100:65-84. doi: 10.1016/B978-0-12-386467-3.00004-2. Review.

PMID:
21971003
18.

Pharmacological interventions in aging and age-associated disorders: potentials of propargylamines for human use.

Kitani K, Minami C, Yamamoto T, Kanai S, Ivy GO, Carrillo MC.

Ann N Y Acad Sci. 2002 Apr;959:295-307. Review.

PMID:
11976204
19.

Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling.

Tatton WG, Chalmers-Redman RM, Elstner M, Leesch W, Jagodzinski FB, Stupak DP, Sugrue MM, Tatton NA.

J Neural Transm Suppl. 2000;(60):77-100. Review.

PMID:
11205159
20.

Is selegiline neuroprotective in Parkinson's disease?

Gerlach M, Youdim MB, Riederer P.

J Neural Transm Suppl. 1994;41:177-88. Review.

PMID:
7931225

Supplemental Content

Support Center